AU2020315605A1 - Polymorphic forms of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide - Google Patents

Polymorphic forms of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide Download PDF

Info

Publication number
AU2020315605A1
AU2020315605A1 AU2020315605A AU2020315605A AU2020315605A1 AU 2020315605 A1 AU2020315605 A1 AU 2020315605A1 AU 2020315605 A AU2020315605 A AU 2020315605A AU 2020315605 A AU2020315605 A AU 2020315605A AU 2020315605 A1 AU2020315605 A1 AU 2020315605A1
Authority
AU
Australia
Prior art keywords
polymorph
composition
degrees
diffraction pattern
theta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020315605A
Other languages
English (en)
Inventor
Jean Alie
Richard DUVOUX
Jean-Philippe JELIN
Olivier Monnier
Philippe Ochsenbein
Min Zhong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myokardia Inc
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of AU2020315605A1 publication Critical patent/AU2020315605A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020315605A 2019-07-16 2020-07-15 Polymorphic forms of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide Pending AU2020315605A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962874855P 2019-07-16 2019-07-16
US62/874,855 2019-07-16
PCT/US2020/042028 WO2021011586A1 (en) 2019-07-16 2020-07-15 Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide

Publications (1)

Publication Number Publication Date
AU2020315605A1 true AU2020315605A1 (en) 2022-03-03

Family

ID=71895284

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020315605A Pending AU2020315605A1 (en) 2019-07-16 2020-07-15 Polymorphic forms of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide

Country Status (14)

Country Link
US (2) US20210053939A1 (https=)
EP (1) EP3999504A1 (https=)
JP (2) JP2022540678A (https=)
KR (1) KR20220035176A (https=)
CN (1) CN114127061A (https=)
AU (1) AU2020315605A1 (https=)
BR (1) BR112022000474A2 (https=)
CA (1) CA3143965A1 (https=)
CL (1) CL2022000050A1 (https=)
CO (1) CO2022000117A2 (https=)
IL (1) IL289817A (https=)
MX (1) MX2022000606A (https=)
PE (1) PE20220645A1 (https=)
WO (1) WO2021011586A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途
CN117865941B (zh) * 2024-03-13 2024-06-28 上海方予健康医药科技有限公司 取代哌啶化合物及其制备方法和应用
WO2025244956A1 (en) 2024-05-20 2025-11-27 MyoKardia, Inc. Methods of manufacturing danicamtiv

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0007784A (pt) 1999-01-27 2002-02-05 American Cyanamid Co Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto
WO2005117882A2 (en) 2004-04-20 2005-12-15 Incyte Corporation Hydroxamic acid derivatives as metalloprotease inhibitors
JP5080970B2 (ja) 2004-06-17 2012-11-21 サイトキネティクス・インコーポレーテッド 心疾患を治療するための置換尿素誘導体
AR055831A1 (es) 2004-12-30 2007-09-12 Janssen Pharmaceutica Nv Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos
KR100979577B1 (ko) 2005-03-03 2010-09-01 에프. 호프만-라 로슈 아게 2형 진성 당뇨병의 치료를 위한11-베타-하이드록시스테로이드 탈수소효소의 억제제로서1-설폰일-피페리딘-3-카복실산 아마이드 유도체
WO2008120759A1 (ja) 2007-03-30 2008-10-09 Japan Tobacco Inc. ウレア化合物およびその用途
US8461209B2 (en) 2007-06-20 2013-06-11 Mitsubishi Tanabe Pharma Corporation Malonic acid sulfonamide derivative and pharmaceutical use thereof
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
RU2443699C2 (ru) 2007-09-20 2012-02-27 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
CN101801952A (zh) 2007-10-01 2010-08-11 弗·哈夫曼-拉罗切有限公司 用作ccr受体拮抗剂的n-杂环联芳基甲酰胺类化合物
MX2010003868A (es) 2007-10-09 2010-04-27 Hoffmann La Roche Cis-imidazolinas quirales.
CN102123990B (zh) 2008-06-19 2014-07-09 武田药品工业株式会社 杂环化合物及其用途
US8324178B2 (en) 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
WO2010113377A1 (ja) 2009-04-01 2010-10-07 パナソニック株式会社 デジタル周波数／位相ロックドループ
CN102596949B (zh) 2009-11-11 2015-08-19 大日本住友制药株式会社 8-氮杂双环[3.2.1]辛烷-8-甲酰胺衍生物
WO2015005305A1 (ja) 2013-07-09 2015-01-15 小野薬品工業株式会社 Ａｌｘｒ作動化合物
NZ717552A (en) 2013-08-07 2021-07-30 Merck Patent Gmbh Piperidine urea derivatives
PL3636649T3 (pl) 2014-01-24 2024-05-06 Turning Point Therapeutics, Inc. Diaryle makrocykliczne jako modulatory kinaz białkowych
IL295547A (en) 2015-01-22 2022-10-01 Myokardia Inc Piperidine-4-methylsulfonyl-modified urea compounds for the treatment of dilated cardiomyopathy (dcm)
WO2020236736A1 (en) 2019-05-19 2020-11-26 MyoKardia, Inc. Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide

Also Published As

Publication number Publication date
US20210053939A1 (en) 2021-02-25
JP2025148397A (ja) 2025-10-07
JP2022540678A (ja) 2022-09-16
US20220289709A1 (en) 2022-09-15
PE20220645A1 (es) 2022-04-28
IL289817A (en) 2022-03-01
CO2022000117A2 (es) 2022-01-17
US12459919B2 (en) 2025-11-04
BR112022000474A2 (pt) 2022-05-17
CA3143965A1 (en) 2021-01-21
MX2022000606A (es) 2022-03-11
CN114127061A (zh) 2022-03-01
TW202116765A (zh) 2021-05-01
CL2022000050A1 (es) 2022-10-14
EP3999504A1 (en) 2022-05-25
KR20220035176A (ko) 2022-03-21
WO2021011586A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
US12459919B2 (en) Polymorphic forms of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1- fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide
ES2953480T3 (es) Compuestos de piperidin-urea sustituida con 4-metilsulfonilo útiles para el tratamiento de trastornos cardíacos como la cardiomiopatía dilatada (CMD)
TWI865562B (zh) (r)-n-(5-(5-乙基-1,2,4-二唑-3-基)-2,3-二氫-1h-茚-1-基)-1-甲基-1h-吡唑-4-羧醯胺之多晶型物
EP3702352A1 (en) Pyrimidinedione compound against cardiac conditions
US10208010B2 (en) Crystal of a heterocyclidene acetamide derivative
US20050032828A1 (en) Piperidine compounds useful as malonyl-CoA decarboxylase inhibitors
WO2008061456A1 (en) The folacin-metformin compound and its manufacture
HUE026984T2 (en) New forms and salts of dihydropyrrol [1,2-C] imidazolyl aldosterone synthase or aromatase inhibitor
TW201010994A (en) Use of soluble epoxide hydrolase inhibitors in the treatment of inflammatory vascular diseases
WO2015192672A1 (zh) 苯并呋喃类衍生物、其制备方法和应用
JP7359460B2 (ja) 心不整脈および心不全の処置のための化合物
TWI921306B (zh) (r)-4-(1-((3-(二氟甲基)-1-甲基-1h-吡唑-4-基)磺醯基)-1-氟乙基)-n-(異噁唑-3-基)哌啶-1-甲醯胺之多晶型物形式
KR20090121832A (ko) 2-(2-히드록시벤조일)히드라진카르복시아미드 유도체 또는이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를유효 성분으로 함유하는 선택적 면역 억제용 약학적 조성물
EP2649996A1 (en) Crystalline forms of sartans like telmisartan with beta blockers
EA052690B1 (ru) Полиморфные формы (r)-4-(1-((3-(дифторметил)-1-метил-1н-пиразол-4-ил)сульфонил)-1-фторэтил)-n-(изоксазол-3-ил)пиперидин-1-карбоксамида
RU2333202C2 (ru) 2-(бутил-1-сульфониламино)-n-[1(r)-(6-метоксипиридин-3-ил)-пропил]бензамид, его применение в качестве лекарственного средства, а также содержащие его фармацевтические композиции
US9073861B2 (en) Diphenylmethyl piperazine derivative and pharmaceutical composition using same
US12552773B2 (en) Compound for specifically enhancing spatial coupling degree of TRPV4-KCa2.3 complex and use thereof
EP2586776A1 (en) Soft cationic mitochondrial uncouplers
JP2021519313A (ja) Ｕｒａｔ−１阻害剤の新規塩型
KR20030002304A (ko) 3-페닐-3,7-디아자비시클로[3.3.1]노난 화합물들과 이들의제조방법 및 이러한 화합물들을 포함하는 약제들
CN103467405B (zh) 一类四氮唑羧酸类化合物、其制备方法和用途
HK40032330A (en) Pyrimidinedione compound against cardiac conditions
HK40027481B (zh) 用於治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物
CN110183348A (zh) N-(3-硝基-4-烷氧基苯甲酰基)氨基酸类化合物、制备方法及其用途